Breaking News

Gilead, South Africa are negotiating a license for local production of new HIV drug 

March 5, 2026
Pharmalot Columnist, Senior Writer
Nardus Engelbrecht/AP

STAT+ | Gilead and South Africa are negotiating a license for local production of new HIV drug

South Africa has the world's highest HIV burden with about 8 million HIV-positive people, or 1 in 5 adults, as of last year

By Ed Silverman


STAT+ | Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance

The new model may appeal to companies, but experts fear it could shift the cost of obtaining the weight loss drug onto workers.

By Elaine Chen


A month in, TrumpRx falls short of president's grand promises

Visits appear to be lagging, few drugs have been added, and some deals with pharma companies are still being worked out.

By Daniel Payne



Vinay Prasad, the director of the FDA's Center for Biologics Evaluation and Research, at left, and his predecessor, Peter Marks, at right.
FDA

STAT+ | The extremism of the FDA's Marks and Prasad has come with costs

In this week's edition of "Adam's Biotech Scorecard," Adam also provides new details on what's at dispute between UniQure and the agency.

By Adam Feuerstein


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments